Fidler Isaiah J, Kripke Margaret L
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 173, Houston, TX, 77030, USA.
Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 173, Houston, TX, 77030, USA.
Cancer Metastasis Rev. 2015 Dec;34(4):635-41. doi: 10.1007/s10555-015-9586-9.
Metastases that are resistant to conventional therapy are the major cause of death from cancer. In most patients, metastasis has already occurred by the time of diagnosis. Thus, the prevention of metastasis is unlikely to be of therapeutic benefit. The biological heterogeneity of metastases presents a major obstacle to treatment. However, the growth and survival of metastases depend on interactions between tumor cells and host homeostatic mechanisms. Targeting these interactions, in addition to the tumor cells, can produce synergistic therapeutic effects against existing metastases.
对传统疗法耐药的转移灶是癌症死亡的主要原因。在大多数患者中，转移在诊断时就已经发生。因此，预防转移不太可能带来治疗益处。转移灶的生物学异质性是治疗的主要障碍。然而，转移灶的生长和存活依赖于肿瘤细胞与宿主稳态机制之间的相互作用。除了肿瘤细胞外，针对这些相互作用可以对现有的转移灶产生协同治疗效果。
